Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and <i>FGFR</i> Alterations: Final Results From the Phase II NORSE Study
First-line erdafitinib monotherapy and erdafitinib plus cetrelimab demonstrated antitumor activity and a manageable safety profile in cisplatin-ineligible patients with mUC.
Authors
- Spyros Triantos
- Meggan Tammaro
- Sydney Akapame
- Taek Won Kang (ORCID: https://orcid.org/0000-0002-7708-819X)
- T. Powles
- Arlene O. Siefker‐Radtke (ORCID: https://orcid.org/0000-0002-6328-9599)
- İrfan Çiçin (ORCID: https://orcid.org/0000-0002-7584-3868)
- Angela Girvin
- Shibu Thomas
- Yohann Loriot
- Wei Zhu
- Anne O'Hagan
- Victor Moreno
Institutions
- St Bartholomew's Hospital (GB)
- Johnson & Johnson (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Queen Mary University of London (GB)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Chonnam National University Hospital (KR)
- Istinye University (TR)
- Hospital Universitario Fundación Jiménez Díaz (ES)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1200/jco-25-00826
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00